Preclinical studies indicated activity of simultaneously inhibiting MDM2 and Bcl‐2 pathways in overcoming resistance to apoptosis,28 and the predicted efficacy was at least partially confirmed in a trial of idasanutlin and venetoclax, which yielded response rates of ~50% in relapsed/refractory AML and was, after dose adjustments, reasonably well tolerated.29 This evidence concerns the gene BCL2 and acute myeloid leukemia.